The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 13, 2015
Filed:
Sep. 19, 2012
Varian Medical Systems, Inc., Palo Alto, CA (US);
Larry Partain, Los Altos, CA (US);
Mingshan Sun, Menlo Park, CA (US);
Edward J. Seppi, Portola Valley, CA (US);
Raisa Pavlyuchkova, Mountain View, CA (US);
Arundhuti Ganguly, San Jose, CA (US);
Stavros Prionas, Menlo Park, CA (US);
James E. Clayton, San Jose, CA (US);
Varian Medical Systems, Inc., Palo Alto, CA (US);
Abstract
Techniques described herein generally relate to identifying, assessing, and managing cancer growth rates and potential metastasis. Some example methods may include constructing one or more quantitative metrics for the potential metastasis in a selected population of other patients, acquiring a first set of numeric biomarker data for the patient before having placed a biomarker in the patient, acquiring a second set of numeric biomarker data for the patient after having placed the biomarker in the patient, determining a set of biomarker surrogate values for microvessel density information based on a mean numeric biomarker difference derived from the first set of numeric biomarker data and the second set of numeric biomarker data, determining a set of biomarker surrogate values for microvessel density information based on a mean numeric biomarker difference derived from the first set of numeric biomarker data and the second set of numeric biomarker data, and predicting quantitative and objective risk for the cancer growth rates and potential metastasis and adjusting a treatment plan based on the biomarker surrogate values and at least one of the one or more quantitative metrics.